Free Trial
NASDAQ:POAI

Predictive Oncology Q1 2025 Earnings Results & Report

Predictive Oncology logo
$8.41 -0.19 (-2.21%)
As of 10/15/2026

Predictive Oncology missed analyst expectations on both earnings and revenue in its Q1 2025 results, released May 14, 2025. The company reported EPS of -$4.80 versus the -$1.35 consensus estimate, while revenue of $0.11 million fell short of the $1.50 million estimate by $1.39 million.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call Date
Conference Call
7:00 AM ET

Predictive Oncology EPS Results

Actual EPS
-$4.80
Consensus EPS
-$1.35
Beat/Miss
Missed by -$3.45
One Year Ago EPS
N/A
EPS Beat Rate
0 of last 6 quarters

Predictive Oncology Revenue Results

Actual Revenue
$0.11 million
Expected Revenue
$1.50 million
Beat/Miss
Missed by -$1.39 million
YoY Revenue Growth
N/A

Predictive Oncology Q1 2025 Earnings FAQ

Predictive Oncology (NASDAQ:POAI) reported earnings of -$4.80 per share for Q1 2025, missing the consensus estimate of -$1.35. The report was announced on Wednesday, May 14, 2025.

Predictive Oncology reported revenue of $0.11 million for Q1 2025, against a consensus estimate of $1.50 million.

Predictive Oncology Earnings Headlines

Financial legend: “This is bad, really bad...”
Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.tc pixel
Predictive Oncology Regains Nasdaq Compliance
See More Predictive Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Predictive Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Predictive Oncology and other key companies, straight to your email.

About Predictive Oncology

Predictive Oncology (NASDAQ:POAI) (NASDAQ: POAI) is a biotechnology company focused on applying artificial intelligence and machine learning to oncology drug discovery and precision medicine. The company combines computational tools with biological data to help identify promising therapeutic candidates and predict how individual tumors may respond to specific treatments.

Its technology platform is built around a proprietary collection of tumor samples and associated clinical and drug-response information. Predictive Oncology uses this data to support pharmaceutical and biotechnology companies in evaluating drug candidates, identifying potential biomarkers, and developing more targeted cancer therapies. The company has also offered tumor-profiling and drug-response testing through its Helomics subsidiary and related operations.

Predictive Oncology’s business has evolved from earlier precision-medicine and cancer-diagnostics activities toward an artificial-intelligence-driven drug discovery model. Its operations and research collaborations have been based primarily in the United States, although the company’s platform is intended to support pharmaceutical and biotechnology partners more broadly. Specific details about its current leadership structure and geographic commercial reach may change over time.

View Predictive Oncology Profile